Preclinical assessment of oral TLR7 agonist SA-5 in a nonhuman primate model

Area of Science:

• Immunology
• Pharmacology
• Drug Development

Background:

• Toll-like receptor 7 (TLR7) agonists are potent immunostimulatory agents.
• Systemic toxicity limits the clinical application of current TLR7 agonists.
• Novel TLR7 agonists with improved safety profiles are needed for treating chronic infections and cancer.

Purpose of the Study:

• To evaluate the pharmacokinetic, safety, and efficacy profile of SA-5, a novel liver-targeted, orally available TLR7 agonist.
• To assess SA-5's performance in young and aged macaques across a range of repeated doses.
• To compare SA-5 with existing TLR7 agonists like GS-9620.

Main Methods:

• SA-5 was administered to young and aged macaques at doses of 1-10 mg/kg.
• Safety was assessed using hematologic, biochemical, and flow cytometric analyses.
• Efficacy was evaluated by measuring IFN-α production, IFN-stimulated gene expression, and plasmacytoid dendritic cell activation.
• A principal component analysis-based composite scoring system integrated multimodal safety and efficacy parameters.

Main Results:

• SA-5 induced dose-dependent type I interferon production with limited systemic inflammation.
• The 3 mg/kg dose of SA-5 demonstrated an optimal balance between efficacy and safety.
• SA-5 exhibited comparable immunostimulatory activity to GS-9620 but with fewer adverse biomarker changes.
• Efficacy was maintained in aged macaques, with only modest increases in safety responses.

Conclusions:

• SA-5 represents a potentially safer, next-generation TLR7 agonist effective across different age groups.
• SA-5's liver-targeted and oral availability enhance its therapeutic potential.
• Integrated biomarker profiling is crucial for preclinical development of immunomodulatory drugs.